Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections

Hiroyuki Kobayashik, Enji Takamura, Hiroaki Takeda, Kota Kono, Akira Saito, Masumi Tomizawa, Ichiro Nakayama, Yohmei Hiraga, Kohki Kikuchi, Asako Yamamoto, Kazuo Takebe, Yoshihiro Kumasakak, Azumi Aoyagi, Toyokazu Tamura, Keiichi Sekino, Katsumi Endo, Tatsuro Irie, Morio Sagara, Katsuhiro Okamoto, Masao TamuraKazuki Konishi, Ataru Daibo, Hiroshi Kuramitsu, Kazutoshi Gomi, Kotaro Itakura, Nobuhisa Sato, Kazuo Tanifuji, Tamotsu Takishima, Shiroh Ida, Isao Ohno, Kiyoshi Konno, Kotaro Oizumi, Seiichi Aonuma, Izumi Hayashi, Masataka Katsu, Shinji Okui, Toshio Fukui, Takashi Yokose, Takeo Toyota, Mieko Kawai, Hajime Yamagata, Shigeo Yoshizawa, Tetsuji Katayama, Teruo Aoyagi, Fuyuhiko Higashi, Gohta Masuda, Masayoshi Negishi, Chenden Young, Minoru Sato, Takehiko Tominaga, Osamu Sekine, Yoshimar Usuda, Nobuki Aoki, Fusanosuke Yamasaku, Yasutoshi Suzuki, Atsushi Saito, Tadashi Miyahara, Masaru Koyama, Kentaro Watanabe, Fukuo Iijima, Keimei Mashimo, Yoshiji Yamane, Masakazu Katoh, Hiroichi Tanimoto, Koichiro Nakata, Yoshitaka Nakamori, Naohiko Chonabayashi, Ryuo Nakatani, Kunihiko Yoshimura, Hideo Ikemoto, Kazuyoshi Watanabe, Junzaburo Kabe, Hiroyoshi Ishibashi, Yasuyuki Sano, Koichiro Kudo, Yuko Uno, Ippei Fujimori, Yoshio Kobayashi, Mitsuo Obana, Takao Okubo, Akira Ito, Makio Kurihara, Kaitaro Yamabe, Kazufuto Fukaya, Fumio Matsumoto, Shigeki Odagiri, Masanori Matsumura, Kaneo Suzuki, Koou Murohashi, Hisako Suzuki, Yasuhiro Yoshiike, Mitsuyo Kiuchi, Tsutomu Fukuda, Shozo Kusama, Yukinori Matsuzawa, Kaoru Ohyama, Toshihiko Takeuchi, Masahito Kato, Hidekazu Hanaki, Toshiyuki Yamamoto, Hideki Nishiyama, Takekuni Iwata, Kazukiyo Oida, Yoshiro Mochizuki, Mitsuo Hase, Yujiro Suzuki, Nobuaki Ikeda, Shozo Fujino, Tetsuya Matsumoto, Hiroyuki Tsujino, Kenji Bando, Naoaki Kuroda, Fumiyuki Kuze, Yuruko Kamoto, Seibun Yonezu, Yube Iida, Yoshihiko Sakakibara, Kōjiro Yasunaga, Yoshihiro Ueda, Hiroshi Ôkubo, Fumio Miki, Yoshiyasu Ikuno, Eiji Inoue, Akihito Murata, Shin Ich Tanizawa, Kazuo Sakamoto, Hirozumi Sakai, Rinzo Soejima, Hiroshi Kawane, Yoshihiti Noki, Yoshihisa Nakagawa, Osamu Moriya, Osamu Kurimura, Hideo Sasaki, Hirofumi Fukuhara, Tadao Morimoto, Eiro Tsubura, Masakazu Tamura, Toshihiro Gotoh, Masaru Nakagawa, Koichi Fukuyama, Tadaaki Morimoto, I. Teiho, Masami Ito, Naoyoshi Kojiro, Yoshiro Sawae, Kaoru Okada, Yukio Kumagai, Hitoshi Nagano, Torao Inoue, Chiharu Kubo, Kohei Hara, Atsushi Saito, Keizo Yamaguchi, Yoji Suzuyama, Yoshiteru Shigeno, Shigeru Kohno, Koichi Watanabe, Kin Ich Izumikawa, Tsunetoshi Koteda, Kazuhiro Okuno, Takashige Miyazaki, Tsuneo Tsutsumi, Keizo Matsumoto, Harumi Shishido, Tomoyuki Harada, Masaru Nasu, Jun Goto, Yoichiro Goto, Takayoshi Tashiro, Takashi Tioga, Shykuro Araki, Masayuki Ando, Moritaka Suga, Kazumine Kobari, Masao Nakatomi, Yutoku Kinjo, Tatsuo Ohgimi, Katsuyoshi Shimoji, Yuei Irabu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The clinical effectiveness, safety and utility of ciprofloxacin (CPFX) in the treatment of chronic respiratory tract infections were compared with those of cefaclor (CCL) by a double dummy fashion. The following diseases were studied in this trial;i. e. infectious exacerbation of chronic bronchitis, diffuse parIbronchiolitis and other respiratory diseases, such as bronchiectasis, bronchial asthma, pulmonary emphysema, pulmonary fibrosis. Patients were orally administered with either 200 mg of CPFX or 250 mg of CCL three times a day for 14 days in principle. Out of all 230 patients, CPFX was given to 111 patients and CCL to 119 patients. Clinical effectiveness, safety and utility were evaluated on the basis of committee judgement and the results obtained were as follows. 1) The clinical effectiveness rate was 84.5% (87/103) in CPFX group and 61.9% (60/97) in CCL group, respectively. Statistically significant difference was observed between the two groups (P< 0.001). 2) Bacteriologically, the eradication rate of 75.0% (45/60) was observed in CPFX group, and that in CCL group was 52.6% (30/57) (P<0.05). The eradication rate of H. influenzae was 90.0% in CPFX group, which was significantly higher than that of the CCL group (P<0.05). 3) Side effects were noted in 5.6% among 107 patients of CPFX group and 6. 1% among 114 patients of CCL group. Abnormal changes in laboratory findings after administration were noted in 11.5% of CPFX cases group and in 11.4% of CCL cases. There was no significant difference between the rates of two groups. 4) The utility rate in CPFX group was 83.5% (86/103), which was higher than that in CCL group (P<0.001). From the above results, CPFX is assessed to be more useful in clinical use than CCL specifically in the treatment of chronic bronchitis, diffuse panbronchiolitis and other chronic complicated or intractable respiratory tract infectious diseases.

Original languageEnglish
Pages (from-to)1011-1037
Number of pages27
JournalChemotherapy
Volume34
Issue number10
DOIs
Publication statusPublished - Jan 1 1986

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

Kobayashik, H., Takamura, E., Takeda, H., Kono, K., Saito, A., Tomizawa, M., ... Irabu, Y. (1986). Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections. Chemotherapy, 34(10), 1011-1037. https://doi.org/10.11250/chemotherapy1953.34.1011